ELISA/assay

Von Willebrand Factor (vWF) ELISA Kit

MBS2022669

48-Strip-Wells

575 USD

ELISA Kit

Von Willebrand Factor (vWF) ELISA Kit

Von Willebrand Factor (vWF)

F8VWF; VWD; von Willebrand antigen 2

von Willebrand factor preproprotein; von Willebrand factor; von Willebrand factor; von Willebrand factor; von Willebrand antigen 2Alternative name(s):von Willebrand antigen II

vWF

VWF; VWF; VWD; F8VWF; F8VWF; vWF

VWF_HUMAN

Canine

351

This assay has high sensitivity and excellent specificity for detection of Von Willebrand Factor (vWF). No significant cross-reactivity or interference between Von Willebrand Factor (vWF) and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Plasma. Assay Type: Competitive. Detection Range: 9.88-800ng/mL. Sensitivity: Typically less than 4.11ng/mL.

Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Von Willebrand Factor (vWF) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Von Willebrand Factor (vWF) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 . Intra-Assay: CV<10% . Inter-Assay: CV<12% . Assay Procedure Summary: 1. Prepare all reagents, samples and standards;. 2. Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix. Incubate 1 hour at 37 degree C;. 3. Aspirate and wash 3 times;. 4. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37 degree C;. 5. Aspirate and wash 5 times;. 6. Add 90uL Substrate Solution. Incubate 15-25 minutes at 37 degree C;. 7. Add 50uL Stop Solution. Read at 450 nm immediately.

Principle of the Assay: This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Von Willebrand Factor (vWF) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Von Willebrand Factor (vWF) and unlabeled Von Willebrand Factor (vWF) (Standards or samples) with the pre-coated antibody specific to Von Willebrand Factor (vWF). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Von Willebrand Factor (vWF) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Von Willebrand Factor (vWF) in the sample.

89191868

NP_000543.2

NM_000552.3

P04275

38,745 Da

Blood Clotting Cascade Pathway (198840); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Focal Adhesion Pathway (198795); Focal Adhesion Pathway (83067); Focal Adhesion Pathway (478); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057)

The glycoprotein encoded by this gene functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease. An unprocessed pseudogene has been found on chromosome 22. [provided by RefSeq, Jul 2008]

VWF: Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Defects in VWF are the cause of von Willebrand disease type 1 (VWD1). A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 2 (VWD2). A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet- dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 3 (VWD3). A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses. Protein type: Secreted, signal peptide; Secreted; Motility/polarity/chemotaxis; Cell adhesion; Extracellular matrix. Chromosomal Location of Human Ortholog: 12p13.3. Cellular Component: extracellular matrix; proteinaceous extracellular matrix; endoplasmic reticulum; extracellular region; external side of plasma membrane. Molecular Function: collagen binding; integrin binding; identical protein binding; protein binding; protein homodimerization activity; protease binding; chaperone binding; protein N-terminus binding; immunoglobulin binding; glycoprotein binding. Biological Process: platelet activation; extracellular matrix organization and biogenesis; platelet degranulation; hemostasis; response to wounding; liver development; blood coagulation; cell adhesion; blood coagulation, intrinsic pathway; cell-substrate adhesion; protein homooligomerization; placenta development. Disease: Von Willebrand Disease, Type 3; Von Willebrand Disease, Type 1; Von Willebrand Disease, Type 2

48-Strip-Wells

575 USD

96-Strip-Wells

785

5x96-Strip-Wells

3055

10x96-Strip-Wells

5495